Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "Global Osteonecrosis Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The osteonecrosis treatment market will register a CAGR of more than 6% by 2023.
The introduction of cell therapy to boost the market growth. The development of stem cells is increasing to engineer advanced stem cells-based treatment that can demonstrate better efficacy and has fewer side effects than the available treatments.
Market Overview
Rising awareness about osteonecrosis
Osteonecrosis is an idiopathic disease as it occurs without trauma and the early diagnosis increases the chances of treatment. Thus, an increasing awareness among people is expected to propel growth in the global osteonecrosis treatment market.
Availability of alternate therapies
The main aim after getting affected by any disease is to get the condition addressed as soon as possible to avoid the progress of osteonecrosis symptoms. Thus, the available treatment are expected to strongly decelerate the growth of the global osteonecrosis market.
For the detailed list of factors that will drive and challenge the growth of the osteonecrosis treatment market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Mylan and Pfizer, the competitive environment is quite intense. Factors such as the rising awareness about osteonecrosis and the expansion of aircraft manufacturing facilities, will provide considerable growth opportunities to osteonecrosis treatment manufactures. Atnahs, Merck Sharp & Dohme, Mylan, Pfizer and Teva Pharmaceutical Industries are some of the major companies covered in this report.
With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- Preface
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2028
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- NSAIDs - Market size and forecast 2018-2023
- Other therapeutics - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
- Introduction of stem cell therapy
- Strategic alliances
- Increasing research for the diagnosis of osteonecrosis
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Atnahs
- Merck Sharp & Dohme
- Mylan
- Pfizer
- Teva Pharmaceutical Industries
PART 14: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/research/vl82bv/global?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.